Navigation Links
NIAID to advance B-cell approach to HIV vaccines

To advance underdeveloped approaches to designing a preventive HIV vaccine, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is launching a new program to foster the study of B cells, immune cells that can produce antibodies with the capacity to neutralize HIV. The $15.6 million, five-year program will strengthen and expand the scientific foundation of HIV vaccine research through a network of 10 research teams nationwide that will share resources, methods and data to accelerate progress.

In the immune system, B cells recognize key parts of microbes, called antigens. Then, in cooperation with T cellsparts of the immune system that kill cells infected by pathogensa reaction is triggered that leads B cells to produce antibodies, which can lock onto antigens and sweep them out of the body. HIV is devilishly good at fooling B cells and shielding itself from antibodies or changing its antigenic parts, so antibodies can rarely rid the body of the virus.

The new NIAID research program aims to uncover mechanisms that will enable scientists to outwit HIV and stimulate the B-cell production of long-lasting antibodies that can neutralize many strains of the virus; such antibodies are known as broadly neutralizing.

This program reflects our commitment to probe the fundamental science underlying HIV vaccine development, says NIAID Director Anthony S. Fauci, M.D. The study of B cells and broadly neutralizing antibodies to HIV will answer pressing, basic scientific questions and bring greater balance to our portfolio of HIV vaccine discovery research.

In recent years, investigator-initiated grants supported by NIAID have focused more heavily on T-cell based approaches to preventive HIV vaccines than on B-cell based ones. Many experts believe a successful HIV vaccine will probably need to activate both T cells and B cells; consequently, NIAIDs creation of the new B-cell research program is an important stimulus for HIV vaccine discovery.

Some evidence suggests that the programs goal of eliciting broadly neutralizing antibodies to HIV, although extremely difficult, may be feasible. Scientists have discovered that some HIV-infected individuals naturally but rarely produce broadly neutralizing antibodies to HIV. Giving such antibodies experimentally to monkeys protected the animals from HIV infection after exposure to the virus. Scientists now face the challenge of how to stimulate the human immune system to predictably produce broadly neutralizing antibodies to HIV through vaccination.

Combining experience with innovation, NIAID is awarding the B-cell program grants to four investigators who already have established a body of research on B cells and antibodies in the context of HIV, and to six investigators with less experience in this area who have exceptionally creative ideas. Each grantees combined expertise in basic immunology and HIV pathogenesis reflects the programs roots in a collaboration between NIAIDs Division of AIDS and its Division of Allergy, Immunology and Transplantation. The joint awards by the two NIAID divisions culminate a 20-month planning and implementation process that began in September 2006. Scientific discussions a year and a half later, during the NIAID HIV Vaccine Summit in March 2008, underscored the importance of broadly neutralizing antibodies as a promising approach that merits further investigation.

The grants are being awarded to the scientists as follows:

Dennis R. Burton, Ph.D.
The Scripps Research Institute

James E. Crowe, Jr., M.D.
Vanderbilt University School of Medicine

Donald N. Forthal, M.D.
University of California, Irvine

Maureen M. Goodenow, Ph.D.
University of Florida College of Medicine

Min Lu, Ph.D.
Weill Cornell Medical College

Abraham Pinter, Ph.D.
University of Medicine and Dentistry of New Jersey

Gerald V. Quinnan Jr., M.D.
Uniformed Services University of the Health Sciences

Ignacio Sanz, M.D.
University of Rochester School of Medicine and Dentistry

Harry W. Schroeder, Jr., M.D., Ph.D.
The University of Alabama at Birmingham

Raul M. Torres, Ph.D.
University of Colorado at Denver and Health Sciences Center


Contact: Laura Sivitz
NIH/National Institute of Allergy and Infectious Diseases

Related medicine news :

1. NIAID describes research priorities to fight drug-resistant tuberculosis
2. NIAID to convene HIV Vaccine Summit
3. NIAID scientists identify new cellular receptor for HIV
4. NIAID strengthens and expands Vaccine and Treatment Evaluation Units
5. NIAID funds $51M contract to create comprehensive model of immune responses
6. Advances Aid Treatment, Diagnosis of Celiac Disease
7. 2008 American Academy of Pediatric Dentistry Annual Session Highlights Emerging Scientific Advancements
8. Partnerships Effective Communicators of Cancer Advances
9. Partnership of academic centers and community hospitals effective model for disseminating advances
10. THE Aesthetic Show Advances $34 Billion Market
11. Singulex Advances Conversation on Personalized Medicine
Post Your Comments:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: